Collaborating Institutions
The ATTRACT Trial boasts an unprecedented degree of interdisciplinary collaboration among subspecialist physicians and leading DVT research institutions. The following partners have worked closely with Washington University in developing ATTRACT, and continue to contribute world-class expertise in clinical trials methodology, venous ultrasound, and economic analysis to the study. 

Ontario Clinical Oncology Group – McMaster University

The Ontario Clinical Oncology Group (OCOG) - Division of Thrombosis, at the Henderson Research Centre at McMaster University in Hamilton, Ontario (Canada), serves as the Data Coordinating Center (DCC) for the ATTRACT Trial. OCOG is renowned for its high level of specialized expertise with the coordination of DVT trials. In recent years, the following completed or ongoing multicenter DVT studies have been coordinated by OCOG: ELATE, DIRECT, SELECT, FLUTE, CANPEDS, LAFIT, D-d RCT, FIDO, PPS, CLOT, SIMPLE, MDA-DVT, SOFAST, and PAPRE. Of the five randomized treatment trials whose results have been submitted for publication, four (LAFIT, ELATE, CLOT, and PAPRE) were published in the New England Journal of Medicine. In addition to its outstanding biostatistical expertise, the OCOG is experienced with quantitative venogram and clinical events adjudication in DVT.

In ATTRACT, the DCC’s primary function is to centrally coordinate the data management for the study. The DCC will work with the CCC to monitor study execution and protocol adherence; coordinate the web-based randomization and online data entry processes; collect, review, and verify submitted Case Report Forms; develop and maintain the study database; coordinate data processing and quality assurance; create the DCC sections of the Manual of Procedures and other study materials; prepare summary information and reports for the various study committees, DSMB, and NHLBI; and perform the final data analysis for the study. The DCC will keep the Steering and Operations Committees apprised of progress and problems, prepare monthly status reports, and act as the Secretariat for the Independent Central Adjudication Committee (ICAC).

VasCore – Massachusetts General Hospital

VasCore, at the Masssachusetts Hospital in Boston, MA, will serve as the Vascular Ultrasound Core Laboratory for the ATTRACT Trial. The Massachusetts General Hospital (MGH) is a 898-bed world-renowned medical center that offers sophisticated diagnostic and therapeutic care in virtually every specialty and subspecialty of medicine and surgery. Each year, the MGH admits approximately 45,000 inpatients and handles almost 1.5 million visits in its extensive outpatient programs at the main campus and at its four health centers in Back Bay, Charlestown, Chelsea, and Revere. Its emergency services handle over 76,000 visits annually. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of nearly $463 million. It is the oldest and largest teaching hospital of Harvard Medical School, and nearly all of the hospital's active staff physicians are on the Harvard Medical School faculty.

The Vascular Ultrasound Core Laboratory (VasCore), established in 1999, is a freestanding, independently functioning unit within the MGH system. VasCore specializes in providing independent ultrasound reading services for clinical trials, and has worked together with the NHLBI and many major pharmaceutical firms and device manufacturers on clinical studies. VasCore has been involved in over 30 clinical trials (about 20 are currently active) involving clinical research sites throughout the world including North America, Europe, and Australia. Specifically, VasCore has participated in the evaluation of device technologies for the carotid, renal, iliac, and lower extremity arteries; abdominal aortic aneurysms, vascular access closure, brachytherapy, and venous valve technology. Vascore is staffed by an administrative director, an office administrator, a technical director, and 3 full-time ultrasound readers who are jointly certified as registered nurses (RN degree) and registered vascular technologists (RVT degree).

In ATTRACT, VasCore will provide instruction on venous Duplex ultrasonography; contribute its ultrasound expertise to the study design; credential the Clinical Center sonographers; develop the ultrasound-related parts of the Manual of Procedures; organize an ultrasound Substudy in which 142 patients will be assessed for valvuar reflux and residual thrombus 1 year after randomization; provide blinded interpretations of Substudy ultrasound exams and selected compression ultrasound exams; and ensure quality control of the ultrasound assessments.

St. Luke’s Mid America Heart Institute

The Health Economics Technology Assessment Group (HETA), an independent functional unit within the Mid America Heart Institute (MAHI) will serve as the Health Economic Core Laboratory for the ATTRACT Trial. Its leaders have tremendous experience in performing health economic evaluations in randomized trials of cardiovascular interventions. HETA-MAHI serves as the Economics and Quality of Life Coordinating Center for 3 other ongoing NHLBI-funded randomized trials: the FREEDOM Trial (2400 patients, 5-years, coronary artery bypass graft surgery vs. percutaneous coronary intervention); the CORAL Trial (1080 patients, 5-years, renal artery stenting vs. medical therapy for renal artery stenosis); and the CREST Trial (2400 patients, 4-years, carotid artery stenting vs. carotid endarterectomy for symptomatic carotid artery stenoses).

In ATTRACT, MAHI will coordinate the collection of economic data on study participants to estimate the costs of the two treatment strategies. If the clot removal treatment is more effective but associated with increased costs, a formal cost-effectiveness analysis will be conducted.

Society of Interventional Radiology (SIR) Foundation

The SIR Foundation is a scientific foundation dedicated to fostering research in interventional radiology for the purposes of advancing scientific knowledge, increasing the number of skilled investigators, and developing innovative therapies that lead to improved patient care and quality of life. The Foundation is committed to fostering the development and enhancement of innovative, minimally invasive, image-guided therapies from inception to mature clinical application and to conduct educational programs in the service of its mission.

The SIR Foundation,played a pivotal role in the genesis of the ATTRACT Trial. In 2004, the SIR Foundation's Cooperative Alliance for Interventional Radiology Research (CAIRR) convened a multidisciplinary research consensus panel (RCP) in order to discuss and establish a research agenda for endovascular venous thromboembolism (VTE) interventions. The expert panel proposed that the most needed research in VTE was a multicenter randomized trial to evaluate interventional clot removal for the treatment of acute DVT. The meeting proceedings were published in the Journal of Vascular and Interventional Radiology in 2005. The SIR Foundation subsequently partnered with Suresh Vedantham, M.D. to develop a venous clinical trials network that was subsequently used to create the network of ATTRACT Study Clinical Centers. The SIR Foundation played a key role in coordinating the site selection process.

During the ATTRACT Study, the SIR Foundation will actively collaborate with the research team. Specifically, the SIR Foundation will assist with maintaining a site selection database; educating physicians, public, and the media about the trial; and disseminating the study results.